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Abstract
Recent work suggests that the 9-repeat (9R) allele located in the 39UTR VNTR of the SLC6A3 gene increases risk of
posttraumatic stress disorder (PTSD). However, no study reporting this association to date has been based on population-
based samples. Furthermore, no study of which we are aware has assessed the joint action of genetic and DNA methylation
variation at SLC6A3 on risk of PTSD. In this study, we assessed whether molecular variation at SLC6A3 locus influences risk of
PTSD. Participants (n=320; 62 cases/258 controls) were drawn from an urban, community-based sample of predominantly
African American Detroit adult residents, and included those who had completed a baseline telephone survey, had provided
blood specimens, and had a homozygous genotype for either the 9R or 10R allele or a heterozygous 9R/10R genotype. The
influence of DNA methylation variation in the SLC6A3 promoter locus was also assessed in a subset of participants with
available methylation data (n=83; 16 cases/67 controls). In the full analytic sample, 9R allele carriers had almost double the
risk of lifetime PTSD compared to 10R/10R genotype carriers (OR=1.98, 95% CI=1.02–3.86), controlling for age, sex, race,
socioeconomic status, number of traumas, smoking, and lifetime depression. In the subsample of participants with available
methylation data, a significant (p=0.008) interaction was observed whereby 9R allele carriers showed an increased risk of
lifetime PTSD only in conjunction with high methylation in the SLC6A3 promoter locus, controlling for the same covariates.
Our results confirm previous reports supporting a role for the 9R allele in increasing susceptibility to PTSD. They further
extend these findings by providing preliminary evidence that a ‘‘double hit’’ model, including both a putatively reduced-
function allele and high methylation in the promoter region, may more accurately capture molecular risk of PTSD at the
SLC6A3 locus.
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Introduction
Posttraumatic stress disorder (PTSD) is a complex disorder
characterized by three symptom clusters including re-experienc-
ing, avoidance, and hyperarousal [1]. Twin studies have shown
that genetic influences account for a substantial proportion (35–
70%) of variance in PTSD risk [2–4]. However, the molecular and
genetic basis of this inherited liability is still largely unknown.
The SLC6A3 (solute carrier family 6 (neurotransmitter trans-
porter, dopamine), member 3; also known as DAT1 or DAT) locus
is a biologically plausible candidate gene for PTSD. SLC6A3
encodes a dopamine transporter, a member of the sodium- and
chloride-dependent neurotransmitter transporter family, which
plays a key role in the regulation of dopaminergic neurotransmis-
sion by removing dopamine from the synaptic cleft via reuptake
through the transporter [5]. The role of dopamine in the etiology
of PTSD is supported by findings of elevated urinary [6] and
plasma [7] levels of dopamine among those affected by the
disorder, and by reports of a significant correlation between
dopamine concentration and severity of PTSD symptoms in
affected individuals [6]. Nevertheless, studies investigating the
association between genetic variation at the SLC6A3 locus and
PTSD have produced conflicting results.
The SLC6A3 locus is characterized by a 40-base-pair variable
number tandem repeat (VNTR) polymorphism in its 39-untrans-
lated region (UTR) which can be present in 3 to 11 copies [8].
Across most populations [9], including African-americans, [9,10]
the 10-repeat (10R) allele is the most frequent followed by the 9-
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have a functional effect on SLC6A3 gene expression; however,
some studies indicate that 10R alleles enhance the SLC6A3 gene
expression compared to 9R alleles whereas others indicate the
opposite [11–18]. Similarly, results investigating the influence of
the SLC6A3 VNTR polymorphism on PTSD risk have been
equivocal, with, for example, the 9R allele related to an increased
risk of PTSD and/or hypervigilance symptoms in three studies
[19–21], but not in an additional, recent multigenerational study
of families exposed to a natural disaster [22].
The complexity of the association between SLC6A3 and PTSD
may be related, in part, to emerging evidence that not only
genetic, but also epigenetic factors shape risk of mental illness.
Epigenetic dysregulation has been implicated in pathogenesis of
several psychiatric disorders such as depression [23], schizophre-
nia [24], eating disorders [25], and PTSD [26,27]. However, little
is known about the epigenetic processes regulating SLC6A3, and
the role of SLC6A3 methylation in PTSD has, to our knowledge,
not yet been reported. To better elucidate the molecular basis
shaping risk of PTSD at the SLC6A3 locus, here we investigate
whether the 9R or 10R allele is associated with lifetime PTSD.
Using specimens drawn from a population-based cohort, the
Detroit Neighborhood Health Study, we assess this putative
PTSD-associated genetic variation in one of the largest datasets
reported to date. We further conduct an exploratory, pilot
investigation of interacting genetic and epigenetic SLC6A3
variation shaping risk of PTSD using a subset of individuals from
our larger genetic dataset.
Materials and Methods
Subjects and Ethics Statement
The Detroit Neighborhood Health Study (DNHS) recruited
1,547 adults aged 18 years or older at baseline from the city of
Detroit. Data for this study were obtained from consenting
participants during this baseline survey year. At wave 1 (baseline),
lifetime trauma exposure and PTSD were assessed using
structured telephone interviews, and each participant received
$25 for their participation in the survey. All survey participants
were offered the opportunity to provide venipuncture (VP) blood
specimens for the biospecimen component of the study (which
included testing of immune and inflammatory markers from serum
as well as genetic testing of DNA) and received an additional $25 if
they elected to do so. VP specimens were obtained via written,
informed consent from a subsample of eligible participants during
wave 1 (n=501). The DNHS was approved by the Institutional
Review Board at the University of Michigan (HUM00014138;
FWA00004969; OHRP IRB IRB00000245). More details regard-
ing the DNHS can be found in [27].
The original sample for this study consisted of 394 individuals,
who were randomly selected from the consenting participants of
the blood draw, blinded to their PTSD status. Because the
diagnosis of PTSD requires a triggering trauma in order to be
expressed, we further restricted our analysis to 362 people who
had experienced one or more traumatic events. The high
prevalence of lifetime trauma exposure in this genotyped sample
(91.9%) is consistent with the prevalence of the full DNHS survey
sample [28] and with earlier work focused on adults in the Metro
Detroit area [29]. Due to the low frequency of 39UTR VNTR
polymorphism of SLC6A3 other than 9R and 10R, only the
individuals carrying 9R/9R, 9R/10R, or 10R/10R genotypes
(n=320; 62 PTSD cases and 258 non-PTSD controls) were
included in the final analysis. The SLC6A3 gene-methylation
interaction was tested in a pilot sample of 83 individuals (16 cases/
67 controls) who also had DNA methylation data.
Assessment of Post-traumatic Stress Disorder and Other
Survey-based Variables
Lifetime PTSD was assessed via telephone interview using a
modified version of the PTSD Checklist (PCL-C) [30], with
additional questions about duration, timing, and impairment or
disability due to the symptoms in order to identify PTSD cases that
were compatible with DSM-IV criteria. Participants were asked to
identify traumatic events they had experienced in the past from a
list of 19 specific events [29], and one additional question that
allowed participants to briefly describe any other stressful event.
Participants who reported experiencing more than one traumatic
event were asked to select one event they considered to be the
worst and report the posttraumatic symptoms due to that specific
event. If participants had experienced more than one trauma, they
were also asked symptoms based on a randomly chosen traumatic
event from the remaining traumatic events. Respondents were
considered affected by lifetime PTSD, if all six DSM-IV criteria
were met in reference to either the worst or the random event. The
identification of PTSD obtained from the telephone interview
responses has been validated in a random subsample of 51
participants via in-person clinical interview, which has been
described previously [27,31]. The comparison showed high
internal consistency and concordance.
Additional survey-based variables included in this study were:
demographic variables including race, sex, and age; number of
traumatic events, known to be strongly associated with PTSD [32–
34],whichwasassessedasacountofthedifferent typesoftraumatic
eventsandrangedfrom0–19foreachperson;whetheraparticipant
had ever smoked, due to the known influence of smoking on DNA
methylation levels [35]; socioeconomic position (SEP); and lifetime
depression, a mental illness frequently comorbid with PTSD [36].
Consistent with the evidence that attainment of more than a high
school education is associated with improved health [37], analyses
were performed with SEP dichotomized according to more than
highschool(highSEP)orhighschoolorless(lowSEP).Assessmentof
the presence/absence of lifetime depression in the DNHS has been
previously reported in detail, and has been validated via clinical in-
person interviews [38].
Genotyping
Samples were genotyped for the SLC6A3 39UTR VNTR using
the primer sets described in Drury et al [19]. Genotyping was
performed on the Mastercycler Pro S thermocycler (Eppendorf,
Hamburg, Germany), using Qiagen’s Taq PCR Core Kit and
associated protocols. Thermocycling conditions included a 94uC
initial at 2 minutes followed by, 35 cycles of: 94uC denature for
15 seconds, 64uC annealing temperature for 15 seconds and a
72uC extension for 30 seconds; and a final temperature of 72uC for
5 minutes. PCR products were then size fractionated on a 2%
agarose gel stained with ethidium bromide. Allele identification
was based on fragments ranging from 3 repeats to 11 repeats, from
known genotypes and sizes standards described in Michelhaugh et
al [11]. Amplification and analysis was performed at least twice for
each individual.
DNA Methylation Microarray Data
Methylation microarray data analysed in this study were
obtained from the HumanMethylation27 (HM27) DNA BeadChip
(Illumina) as previously described [27]. Bisulfite-converted DNA
samples were subjected to methylation profiling via the Human-
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manufacturer’s instructions. Methylation levels were determined
for 27,578 CpG dinucleotides spanning 14,495 genes. The
resulting data were background normalized using Bead Studio.
The validation of the methylation microarray data via pyrose-
quencing and DNA sequencing of a subset of individuals tested on
the original microarray were conducted and has been reported in
detail elsewhere [27]. For the purpose of this study, methylation of
SLC6A3 was assessed at two CpG sites represented on the HM27
BeadChip. The first CpG site (cg13202751) occurs approximately
900bp upstream of the SLC6A3 gene within its putative promoter
region. The second CpG site (cg26205131) is located in the first
intron of the SLC6A3 gene, between the upstream 59-UTR and the
downstream start codon (,1.5 kb).
Pyrosequencing Validation
Locus-specific pyrosequencing was conducted to validate the
methylation data at cg13202751. Pyrosequencing assays were
designed and implemented by EpigenDx (Worcester, MA)
following the manufacturer’s recommended protocol. Since the
microarray and the pyrosequencing methylation data were not
normally distributed in our sample, we evaluated the correlation
between the two using the Spearman’s rank order correlation test.
We observed a moderate but significant correlation between the
two variables based on available DNA samples from 69 of the
original 83 individuals tested in the microarray analysis (Spear-
man’s r=0.31, p=0.009).
Statistical Analysis
Chi-square tests were performed to verify Hardy-Weinberg
equilibrium. We calculated means with standard deviations for
continuous covariates. For categorical covariates, frequencies and
percents were calculated. Bivariate associations were assessed for
each of the variables of interest and covariates with respect to
lifetime PTSD status. The chi-square test was performed for
categorical variable comparisons; for continuous variable com-
parison, two-sample t-tests were used. SLC6A3 39UTR VNTR
genotypes of 9R/9R and 9R/10R were combined into the ‘9R
carrier’ category due to a small number of individuals with 9R/9R
genotype (n=15). Logistic regression analysis, adjusting for
potential confounders and known predictors of PTSD, including
age, sex, socio-economic position, race, smoking, number of
traumatic events, and lifetime depression, was used to assess the
main effect of SLC6A3 VNTR polymorphism on the risk of lifetime
PTSD, which was coded as a dichotomous variable. Continuous
variables including age and number of traumatic events were
centered to the mean.
Because the odds ratio estimation in logistic regression could be
unreliable (i.e. overestimated) when sample size is not large, the
exact logistic test was used when analyzing the pilot sample
consisting of those who also had SLC6A3 microarray methylation
data (n=83) to ensure a valid inference in such situation. The
same covariates as in the genotype analysis plus peripheral blood
mononuclear cell (PBMC) counts (collected as previously described
in [38]), were adjusted for to assess the main and interacting effects
of SLC6A3 genetic and epigenetic variation on lifetime risk of
PTSD. In the exact logistic test, all continuous variables were
dichotomized by the median value except the total number of
PTEs to make the exact test computationally feasible. Due to the
limited variation in the methylation beta-values at cg26205131
(Figure S1), our statistical analysis focused on cg13202751.
Methylation beta-values at cg13202751were dichotomized based
on the median value (median-split; 0.19) to improve the estimation
stability of the logistic regression models. In all analyses, p-values of
less than 0.05 (two-tailed) were considered as evidence of statistical
significance. The analyses were conducted with SAS version 9.2
(SAS Institute, Cary, NC).
Results
Full Analytic Sample
In Table 1, we present the frequencies of all SLC6A3 39-UTR
alleles for all 362 trauma exposed participants. The descriptive
statistics and bivariate results based on the 320 trauma exposed
study participants with either 9R/9R, 9R/10R, or 10R/10R
genotypes are shown in Table 2. The majority of participants
(79.3%) were of African American descent. The lifetime preva-
lence of PTSD in this sample was 19.4%. Compared to individuals
without PTSD, PTSD cases reported significantly greater number
of traumatic events (p , 0.001), were more likely to have ever
smoked (p=0.02), and were more likely to have met lifetime
criteria of depression (p , 0.001). The SLC6A3 genotype
distribution for participants carrying a 9R or 10R allele did not
depart from Hardy-Weinberg equilibrium (p=0.15). After adjust-
ing for age, sex, socio-economic status, race, smoking, number of
traumatic events and lifetime depression, 9R allele carriers showed
almost twice the risk of PTSD compared to 10R/10R carriers
(OR=1.98, 95% CI=1.02–3.86) (Table 2).
DNA Methylation Subsample
The lifetime prevalence of PTSD in the DNA methylation
subsample was 19.2%. Similar to the full analytic sample,
participants with PTSD in the methylation subsample reported a
significantly greater number of traumatic events (p=0.001), were
more likely to have ever smoked (p=0.01), and were marginally
more likely to have met lifetime criteria of depression (p=0.06)
compared to non-PTSD affected participants. Mean DNA
methylation beta-values at cg13202751 did not differ significantly
by PTSD status (p=0.56).
Inmaineffectanalyses(Table3),therewasnosignificantevidence
of association between high methylation level at SLC6A3 CpG site
cg13202751 and lifetime PTSD after adjusting for age, sex, socio-
economic position, race, smoking, number of traumatic events,
PBMC counts, and lifetime depression (p=0.39). However, results
from the exact logistic regression test for lifetime risk of PTSD
indicated a significant SLC6A3 genotype6methylation interaction
(p=0.008). Specifically, 9R allele carriers showed an increased risk
of lifetime PTSD only in conjunction with high methylation at
cg13202751 located within the SLC6A3 promoter locus.
Table 1. Allele frequencies of SLC6A3 39-UTR VNTR
polymorphism in trauma-exposed participants (n=362).
Allele Frequency Percent (%)
3R 28 3.93
7R 5 0.70
8R 14 1.97
9R 126 17.70
10R 537 75.42
11R 2 0.28
Missing* 12 –
*6 individuals failed SLC6A3 3-‘UTR VNTR genotyping.
doi:10.1371/journal.pone.0039184.t001
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In this work, we have explored how genetic and epigenetic
molecular variation at the SLC6A3 locus shapes risk of PTSD. Our
findings confirm previous work indicating that 9R allele carriers of
the SLC6A3 39UTR VNTR polymorphism show significantly
increased risk of lifetime PTSD compared to 10R/10R genotype
carriers [19–21]. In addition, we provide preliminary, new
evidence that interacting genetic and epigenetic variation at the
SLC6A3 locus shapes risk of PTSD, with participants who carried
9R alleles and possessing high DNA methylation at cg13202751
showing significantly increased risk of the disorder. Although these
preliminary findings await confirmation, we suggest that an
integrated model that simultaneously investigates the interaction
between genetic polymorphisms and epigenetic alterations, as
conducted here, may contribute to a more comprehensive picture
of the complex molecular etiology shaping risk of PTSD.
Our findings have several implications. First, our results provide
indirect support that may help to resolve whether the 9R [11] or
10R SLC6A3 allele is associated with higher transcription levels
[12,14,17]. Given the association between elevated dopamine
levels and posttraumatic symptoms, discussed in the introduction,
our own observation of a significantly increased risk of PTSD in
9R allele carriers suggests that the 9R allele may result in
Table 2. Descriptive statistics and bivariate comparisons of participants with and without lifetime PTSD and effect of SLC6A3
39UTR VNTR polymorphism on risk of lifetime PTSD in the full analytic sample* (n=320).
Overall trauma exposed
sample (n=320)
non-PTSD
controls (n=258)
PTSD cases
(N=62) Main effect model
Characteristic N % N % N % p-value OR 95% CI of OR p-value
Age** 51.6 15.76 52.19 16.15 61 49.1 0.17 1 0.98 1.02 0.94
Female 186 58.13 146 56.59 40 64.52 0.26 1.52 0.77 2.96 0.23
Low SES 149 46.56 114 44.19 35 56.45 0.08 2.69 1.37 5.3 ,0.01
African American 253 79.31 199 77.43 54 87.1 0.09 1.86 0.74 4.69 0.19
Ever smoke 207 64.69 159 61.63 48 77.42 0.02 2.19 1.01 4.72 0.05
Lifetime depression 76 23.82 43 16.73 33 53.23 ,0.0001 5.55 2.74 11.21 ,0.0001
Number of PTEs** 5.95 3.56 5.42 3.28 8.16 3.83 ,0.0001 1.19 1.08 1.31 ,0.001
SLC6A3 39-UTR VNTR genotype
9R carriers 104 32.5 79 30.62 25 40.32 0.14 1.98 1.02 3.86 0.04
10R/10R 216 67.5 179 69.38 37 59.68 1 (referent group)
SES: socio-economic status; PTEs: potential traumatic events; UTR: untranslated region; VNTR: variable number tandem repeat.
*Full analytic sample includes 320 participants who were trauma exposed and had SLC6A3 39-UTR VNTR polymorphism of either 9R/9R, 9R/10R, or 10R/10R genotypes.
**Variables are presented by mean and standard deviation.
doi:10.1371/journal.pone.0039184.t002
Table 3. Main effects of SLC6A3 39UTR VNTR polymorphism and promoter region methylation and interactive on risk of lifetime
PTSD in the methylation subsample (n=83).
Adjusted Models Main effect - SLC6A3 VNTR genotype Interaction model
Characteristic OR 95% CI of OR p OR 95% CI of OR p
Age* 0.47 0.08 2.40 0.49 0.29 0.02 2.24 0.35
Female 1.31 0.24 7.37 1.00 1.13 0.14 9.18 1.00
Low SES 3.25 0.73 18.86 0.15 18.19 1.79 .999.99 ,0.01
African American 0.55 0.08 4.10 0.74 0.82 0.08 10.77 1.00
Ever smoke 5.37 0.90 63.32 0.07 11.08 0.86 868.49 0.08
PBMC counts* 0.49 0.10 2.11 0.44 0.72 0.13 3.82 0.92
Number of PTEs
{ 1.25 1.04 1.54 0.02 1.44 1.10 2.04 ,0.01
Lifetime depression 2.29 0.43 13.11 0.43 2.37 0.35 18.29 0.52
SLC6A3 methylation *
,{ 2.34 0.47 13.74 0.39 0.31 0.02 3.14 0.47
SLC6A3 VNTR genotype 1.69 0.34 8.33 0.67 0.05 ,0.001 1.46 0.11
SLC6A3 methylation x genotype interaction – – – – 48.61* 2.73 Infinity ,0.01
SES: socio-economic status; PTEs: potential traumatic events; UTR: untranslated region; VNTR: variable number tandem repeat; PBMC: peripheral blood mononuclear cell
counts.
*Median-split.
{Continuous, centered to the mean.
{Assessed at cg13202751.
doi:10.1371/journal.pone.0039184.t003
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mined with certainty without further functional studies. Second,
our results highlight the importance of considering how molecular
variation, at multiple levels, can shape risk of complex illnesses like
PTSD. Although the relationship between DNA methylation and
gene expression is complex, increased promoter-region DNA
methylation is typically thought to correlate with decreased gene
transcription [39]. Our results identified a significant genotype x
methylation interaction, whereby individuals who have the
‘‘double hit’’ risk factors of both a putatively reduced-function
9R allele and high promoter region SLC6A3 methylation exhibited
significantly elevated risk of PTSD. We speculate that these
individuals are likely to have elevated dopamine levels in the
synaptic cleft that may, in turn, contribute to increased risk of
PTSD, but future work in other independent samples is warranted
to confirm this initial finding.
The study has several strengths. First, compared to prior studies,
this study had a relatively large total sample size. Second, it is the
first study that assessed the effect of the SLC6A3 39 UTR VNTR
variant on the risk of PTSD in a population-based sample, which
reduces potential biases of non-compatibility between cases and
controls compared to clinic-based samples or volunteers. Third, no
prior studies, to our knowledge, have considered the role of DNA
methylation when assessing the involvement of SLC6A3 in PTSD;
similarly, none have considered the joint action of SLC6A3 genetic
and DNA methylation variation on risk of PTSD. This study thus
broadens existing knowledge by identifying the ways in which both
forms of SLC6A3 molecular variation shape the risk of PTSD.
Limitations of our study include a relatively small sample size
with which to test DNA methylation effects on risk of PTSD; we
also note that our results were not corrected for multiple testing in
the methylation subsample analyses. In addition, because there are
few participants with 39UTR VNTR homozygous 9R genotypes,
we were unable to specifically investigate the effects between
homozygous and heterozygous 9R carriers on the risk of PTSD.
Furthermore, we were unable to directly assess the relation
between 9R vs. 10R alleles on SLC6A3 gene expression levels as
the samples tested in this work were not collected in a manner that
preserved RNA. Finally, due to the cross-sectional analysis of
blood specimens and questionnaire data, the temporal relationship
between SLC6A3 methylation differences and PTSD onset remain
unclear. Ongoing work using samples from this same longitudinal
cohort should help to shed light on this issue.
Despite these limitations, results of this study support an
important role for the dopamine transporter in PTSD. Our
findings are in accordance with studies favoring the 9R allele of
the SLC6A3 39UTR VNTR polymorphism as a risk allele for
PTSD compared to the homozygous 10R genotype. In addition,
to the best of our knowledge, we report the first, albeit preliminary,
simultaneous investigation of SLC6A3 genetic and epigenetic
variation on the lifetime risk of PTSD. Individuals had the highest
risk of PTSD when they both carried a 9R allele at the 39UTR
VNTR and had showed hypermethylation at a CpG site located in
the SLC6A3, offering a potential molecular mark of increased risk
for PTSD. Future studies conducted on other, independent
cohorts should help to confirm the generalizability of our findings.
Supporting Information
Figure S1 DNA methylation beta-value distributions of
SLC6A3 at the two CpG sites (cg13202751 and
cg26205131) represented on the HM27 beadchip.
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